ストックスクリーナーアプリを入手
62.62
0.79%
-0.50
アフターアワーズ：
62.62
Monopar Therapeutics Inc (MNPR) 最新ニュース
What triggered Monopar Therapeutics shares' latest price pullback - Traders Union
Monopar Therapeutics stock price forecast: Holding $60.25 support as MNPR declines 2.47% - Traders Union
Monopar Therapeutics Q1 2026 Earnings: Narrower Loss Surprises MarketEarnings Outlook Update - Newser
Monopar Therapeutics Presents Positive Phase 2 Results for ALXN1840 in Wilson Disease Patients - Minichart
Monopar reports positive Wilson disease trial data publication By Investing.com - Investing.com South Africa
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data - TipRanks
Monopar reports positive Wilson disease trial data publication - Investing.com India
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease - The Manila Times
Monopar Therapeutics Publishes Phase 2 Trial Results of ALXN1840 for Wilson Disease in Hepatology Communications - Quiver Quantitative
Drug trial helps Wilson disease patients shed excess copper - Stock Titan
ALXN1840 Wilson disease trial data published by Monopar (NASDAQ: MNPR) - Stock Titan
Chardan Capital Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN
Discipline and Rules-Based Execution in MNPR Response - Stock Traders Daily
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Cuts Target Price to $59.27 - Moomoo
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail
Saturn V, Xiaoying Tian report 345,626 MNPR shares (5.20%) — MNPR - Stock Titan
Monopar Buy Rating Reiterated on Advancing ALXN1840 Profile and De-Risked Regulatory Path; $104 Price Target Unchanged - TipRanks
A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $104 to $130 - Moomoo
Is Monopar Therapeutics (MNPR) Undervalued After Q1 2026 EPS Bea - GuruFocus
Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Monopar Therapeutics reports Q1 2026 loss, advances ALXN1840 NDA submission for Wilson disease. - Pluang
Monopar Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Monopar (NASDAQ: MNPR) ends Q1 with $137.5M cash and funds through 2027 - Stock Titan
Monopar Therapeutics 1Q 2026: Revenue ($3.93M), Net income ($3.89M), EPS ($0.46) — 10-Q Summary - TradingView
Monopar Therapeutics Reports Q1 2026 Financial Results and Updates on ALXN1840 Development for Wilson Disease - Quiver Quantitative
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Monopar Therapeutics reports Q1 2026 net loss $3.9M, cash $137.5M; NDA on track for mid-2026 - TradingView
Cash runway to 2027 as Monopar (NASDAQ: MNPR) readies ALXN1840 - Stock Titan
Press Release: Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - Moomoo
Monopar Therapeutics stock (US6093601054): Clinical-stage biotech focused on oncology innovations - AD HOC NEWS
Adage (MNPR) reports 424,195 shares, including 115,000 warrant shares - Stock Titan
Monopar Therapeutics stock (US6093601054): Shares up 3% at $65.52 - AD HOC NEWS
TradingKey - TradingKey
The long term thesis for Monopar Therapeutics (MNPR) in plain sight (Smart Money Outflows) 2026-05-08Rising Community Picks - Newser
Behavioral Patterns of MNPR and Institutional Flows - Stock Traders Daily
Number of shareholders of Monopar Therapeutics Inc – MUN:1IY0 - TradingView
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
[ARS] Monopar Therapeutics SEC Filing - Stock Titan
[DEF 14A] Monopar Therapeutics Definitive Proxy Statement - Stock Titan
(MNPR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MNPR (Monopar Therapeutics Inc.) slips 2.56% after Q4 2025 earnings miss on larger than expected per share loss.ROIC - Xã Thanh Hà
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR) - ChartMill
Monopar Therapeutics stock maintained at Buy by Lake Street on trial data - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR) and Agios Pharma (AGIO) - The Globe and Mail
Monopar Therapeutics stock maintained at Buy by BTIG on trial data - Investing.com Canada
Monopar Reports Phase 3 Data Showing ALXN1840 Provides Greater Neurologic Benefit Versus Standard of Care in Wilson Disease Patients - Minichart
ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification - TipRanks
Monopar Highlights Strong Phase 3 Data for ALXN1840 - TipRanks
Monopar (MNPR) unveils Phase 3 ALXN1840 neurologic gains and plans mid-2026 NDA - Stock Titan
Lake Street Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN
MNPR (Monopar Therapeutics) posts wider Q4 2025 loss and zero revenue, shares dip 1.5 percent on weak results. - Newser
Monopar Therapeutics (MNPR) Shows Promising Results in Wilson Di - GuruFocus
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 - The Manila Times
Monopar Therapeutics Reports Positive Phase 3 Trial Results for ALXN1840 in Wilson Disease Patients at AAN Annual Meeting 2026 - Quiver Quantitative
Wilson disease study: 9% worsened on ALXN1840 vs 25% on standard care - Stock Titan
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Monopar Therapeutics (MNPR) Stock Sector Perform (Weakens) 2026-04-16High Volume Stocks - Xã Vĩnh Công
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):